← Biofrontera Inc. (BFRI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Biofrontera Inc. (BFRI)
Pharmaceutical Preparations · market cap $17M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Biofrontera Inc. (BFRI) is a micro-cap pharmaceutical company with a market capitalization of approximately $13M and a share price near $1.05. Its pipeline is anchored by BF-200 ALA gel in Phase 3 for Actinic Keratosis (AK) and methyl-aminolevulinate in Phase 3 for Basal Cell Carcinoma (BCC). Key financial metrics including cash position, runway, and dilution history are not disclosed in available data.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BF-200 ALA gel | Phase 3 | Actinic Keratosis |
| BF-200 ALA | Phase 3 | Actinic Keratosis |
| methyl-aminolevulinate | Phase 3 | Basal Cell Carcinoma (BCC) |
| BF-200 ALA 1% | Phase 2 | Actinic Keratosis |
Price & technical context
3-month
-12.9%
6-month
+3.1%
12-month
-1.0%
52-wk range
$0.57–$1.61
vs 50-day MA
-22.7%
vs 200-day MA
-1.3%
Realized vol
80.1%
Max drawdown
-57.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BFRI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.